The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

Movement Disorders

Volumn 14, Issue 5, 1999, Pages 744-753

  Henry, Brian ^b   Fox, Susan H ^a   Peggs, David ^a   Crossman, Alan R ^a   Brotchie, Jonathan M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

2 adrenergic receptor antagonists; 1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP) lesioned marmoset; Idazoxan; L dopa induced dyskinesia; Parkinson's disease

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; IDAZOXAN; LEVODOPA; RAUWOLSCINE; YOHIMBINE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DYSKINESIA; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MARMOSET; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ANIMAL; BRAIN; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; METABOLISM; TIME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADRENERGIC ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CALLITHRIX; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DYSKINESIAS; FEMALE; IDAZOXAN; LEVODOPA; MALE; RECEPTORS, ADRENERGIC, ALPHA-2; TIME FACTORS; YOHIMBINE;

EID: 0032588996     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7     Document Type: Article

References (46)

1. Nutt JG. Levodopa induced dyskinesia: review. Observations and speculations. Neurology 1990;40:340-345.
2. Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997;20:95-115.
3. Hurtig HI. Problems with current pharmacological treatment of Parkinson's disease. Exp Neurol 1997;144:10-16.
4. 3H]-spiperone binding. Brain Res 1986;379:294-299.
5. Kartzinel R, Teychenne P, Gillespie MM. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet 1976;2: 272-275.
6. Parkes JD, Debono AG, Marsden CD. Bromocriptine in parkinsonism: long-term treatment dose response, and comparison with levodopa. J Neurol Neurosurg Psychiatry 1976;39:1101-1108.
7. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023.
8. Ogawa N, Kanazawa I, Kowa H, et al. Nation-wide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Eur Neurol 1997;38(suppl 2):37-49.
9. Lees AJ. Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307:469-472.
10. Calne DB, Plotkin C, Williams AC, et al. Long-term treatment of parkinsonism with bromocriptine. Lancet 1978;1:735-738.
11. Hoehn MM. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease. Acta Neurol Scand 1985;71:97-106.
12. Bedard PJ, Mantilla BG, Blanchett P, et al. Levodopa-induced dyskinesia: facts and fancy. What dose the MPTP monkey model tell us? Can J Neurol Sci 1992;19:134-137.
13. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
14. Pearce RKB, Banerji T, Jenner P, et al. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998;13:234-241.
15. 2A antagonist: a novel anti-parkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
16. Mitchell IJ, Hughes N, Carroll CB, et al. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulation of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA-lesioned marmoset. Behav Pharmacol 1995;6:492-507.
17. Nutt JG, Carter JH, Woodward WR. Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the anti-parkinsonian effects. Neurology 1994;44:1617-1622.
18. Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients. Brain 1991;114:601-617.
19. Rascol O, Fabre N, Blin O, et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 1994;9:437-440.
20. Gomez-Mancilla B, Bedard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427.
21. 2-adrenoreceptor. Pharmacol Rev 1983;35: 143-180.
22. Marwaha J, Aghajanian GK. Relative potencies of alpha-1 and alpha-2 antagonists in the locus ceruleus, dorsal raphe and dorsal lateral geniculate nuclei: an electrophysiological study. J Pharmacol Exp Ther 1982;222:2:287-293.
23. Scatton B, Zivkovic B, Dedek J. Anti-dopaminergic properties of yohimbine. J Pharmacol Exp Ther 1980;215:494-499.
24. Cole JC, Burroughs GJ, Laverty CR, et al. Anxiolytic-like effects of yohimbine in the murine plus-maze: strain independence and evidence against alpha 2-adrenoceptor mediation. Psychopharmacology 1995;118:425-436.
25. Tallentire D, McRae G, Spedding M, et al. Modulation of sexual behaviour in the rat by a potent and selective alpha2-adrenoceptor antagonist, delequamine (RS-15385-197). Br J Pharmacol 1996; 118:63-72.
26. Borman RA, Burleigh DE. Functional evidence for a 5-HT2B receptor mediating contraction of longitudinal muscle in human small intestine. Br J Pharmacol 1995;114:1525-1527.
27. Thomas DR, Faruq SA, Balcarek JM, et al. Pharmacological characterisation of [35S]-GTPγS binding to Chinese hamster ovary cell membranes stably expressing cloned human 5-HT1D receptor subtypes. J Recept Signal Transduct Res 1995;15:199-211.
28. Doxey JC, Lane AC, Roach AG, et al. Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn Schmiedebergs Arch Pharmacol 1984;325:136-144.
29. 3HJRauwolscine (α-yohimbine): a specific antagonist radioligand for brain α2-adrenergic receptors. Eur J Pharmacol 1981;76:461-464.
30. Pearce RK, Jackson M, Smith L, et al. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 1995;10:731-740.
31. Brotchie JM, Fox SH, Henry B, et al. The cannabinoid receptor antagonist SR 141716A reduces L-dopa-induced dyskinesia in the MPTP-treated primate model of Parkinson's disease [Abstract]. Br J Pharmacol 1998;123:P66.
32. Marconi R, Lefebvre CD, Bonnet AM, et al. Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
33. Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioural responses to L-dopa following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998;151:334-342.
34. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease, inter- and intra-rater reliability assessment. Mov Disord 1994;9:390-394.
35. Langston JW, Widner H, Goetz CG, et al. Core Assessment Program for Intracerebral Transplantations (CAPIT). Mov Disord 1992;7:2-13.
36. Dettmar PW, Lynn AG, Tulloch IF. Neuropharmacological studies in rodents on the action of RX 781094, a new selective alpha 2-adrenoceptor antagonist. Neuropharmacology 1983;22:729-737.
37. Unnerstall JR, Kopajtic TA, Kuhar MJ. Distribution of α2-agonist binding sites in the rat and human central nervous system: analysis of some functional anatomic correlates of the pharmacological effects of clonidine and related adrenergic agents. Brain Res 1984; 319:69-101.
38. Scheinin M, Lomasney JW, Hayden HD, et al. Distribution of α2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 1994;21:133-149.
39. 2C-adrenergic receptor-like immunoreactivity in the rat central nervous system. J Comp Neurol 1996;372:135-165.
40. 2C-adrenoceptor immunoreactivity with GABA, calbindin D28K and parvalbumin immunoreactivity in rat striatal neurons [Abstract]. Soc Neurcsci 1997;23:586.1.
41. Crossman AR. An hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
42. Colpaert FC, Degryse AD, Van Craenendonck HV. Effects of an alpha 2 antagonist in a 20-year-old Java monkey with MPTP-induced parkinsonian signs. Brain Res Bull 1991;26:627-623.
43. 2 antagonist, in Parkinson's disease [Abstract]. Mov Disord 1996;11(suppl 1):116.
44. Ozaita A, Olmos G, Boronat MA, et al. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver. Br J Pharmacol 1997;121:901-912.
45. 2-adrenoreceptor antagonists in the MPTP-marmoset model of L-dopa induced dyskinesia [Abstract]. J Neurol Neurosurg Psychiatry 1998;14:695.
46. 2 antagonist, idazoxan, in patients with Parkinson's disease [Abstract]. Mov Disord 1997;12:111.